CytRx Corporation (NASDAQ: CYTR) today provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE